FDA Names First AI Deputy Commissioner Amid Leadership Shifts

The U.S. Department of Health and Human Services announced on Monday that it has confirmed four senior leaders for the Food and Drug Administration. This move stabilizes the agency’s operational structure after months of turnover following the departure of Commissioner Marty Makary in May. The appointments convert interim arrangements into permanent roles for the directors of the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.

Most significantly, the agency has created its first-ever Deputy Commissioner for Technology and Artificial Intelligence. According to reports from GN technics/ai (en-US), this new role places AI governance above the center directors, signaling that the administration intends to treat artificial intelligence as a cross-agency priority rather than a departmental initiative. The appointment aims to streamline how the FDA evaluates new technologies in drug development and safety.

New Leadership Focuses on Drug Access

Michael Davis has been confirmed as the permanent director of the Center for Drug Evaluation and Research. His agenda centers on three main priorities: increasing patient access to safe and affordable medicines, advancing the science of drug development, and strengthening the global drug supply chain. This permanent appointment is particularly significant for pharmaceutical sponsors who have navigated a period of frequent leadership changes within the center.

Karim Mikhail has also been confirmed as the director of the Center for Biologics Evaluation and Research. With more than two decades of experience in the biotechnology sector, his priorities include modernizing regulatory frameworks to accelerate development for rare diseases. He also emphasizes strengthening vaccine safety surveillance with a commitment to transparency, addressing areas that have faced significant scrutiny under the current administration.

AI Governance Becomes Agency Priority

Jared Seehafer will lead the newly created deputy commissioner role for Technology and AI. Bringing two decades of experience at the intersection of software and medical technology, his position is designed to oversee the agency's approach to artificial intelligence. This structural change ensures that AI considerations are integrated into all regulatory processes, from clinical trials to final product approval, rather than being handled in silos.

The creation of this role comes as the FDA issues new guidance on AI use in regulatory submissions. It also addresses the agency's need to manage a surge in drug warning letters, some of which have been attributed to technical deficiencies. By elevating AI oversight to the deputy level, the FDA aims to provide clearer standards for how companies can leverage these tools without compromising safety.

Stability Amid Regulatory Uncertainty

While these appointments provide immediate stability, the long-term consistency of FDA reviews will depend on the execution of these new leadership teams. The confirmation of a permanent commissioner is still pending, which remains a key variable for industry planning. However, the permanent status of the center directors reduces near-term organizational churn and offers a clearer path for stakeholders.

HHS Secretary Robert F. Kennedy Jr. stated that these leaders will drive the reforms needed to confront serious health challenges. The agency aims to move faster and demand excellence while delivering results for the public. This shift reflects a broader effort to balance regulatory rigor with the need for innovation and accessibility in the healthcare sector.